Perrigo (NYSE:PRGO) is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution. Its Consumer Healthcare division produces store-brand formulations for allergy relief, cold and flu, pain management, dermatology and women’s health. The Prescription Pharmaceuticals arm offers generic alternatives to branded drugs in areas such as dermatology and women’s health, while its Active Pharmaceutical Ingredients segment supplies key raw materials used by other drug manufacturers.
Founded in 1887 by Luther Perrigo in Allegan, Michigan, the company has grown through both organic innovation and strategic acquisitions, including the purchases of Paddock Laboratories and Omega Pharma. In 2013, Perrigo re-domiciled to Ireland and established its headquarters in Dublin, reflecting its expanded international footprint. Today, the company serves markets across North America, Europe, the Middle East, Africa and Asia-Pacific, operating manufacturing facilities and research centers in multiple regions. Perrigo’s commitment to product quality, regulatory compliance and sustainable manufacturing underpins its mission to deliver accessible healthcare solutions worldwide.
